Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial

Ariane Mamguem Kamga, Cyril Di Martino, Amelie Anota, Sophie Paget-Bailly, Charles Coutant, Patrick Arveux, Isabelle Desmoulins, Tienhan Sandrine Dabakuyo-Yonli, Ariane Mamguem Kamga, Cyril Di Martino, Amelie Anota, Sophie Paget-Bailly, Charles Coutant, Patrick Arveux, Isabelle Desmoulins, Tienhan Sandrine Dabakuyo-Yonli

Abstract

Background: Despite its proven efficacy in reducing recurrence and improving survival, adherence to endocrine therapy (ET) is suboptimal in women with breast cancer (BC). Health-related quality of life (HRQoL) in BC has been widely studied and many positive effects have been highlighted. Recently, a link between HRQoL and compliance with ET has been suggested, which would suggest a potential role for HRQoL assessment in improving compliance with ET. With the advent of digital technologies, electronic collection of HRQoL on a tablet is now possible. Thus, we hypothesize that systematic HRQoL assessment (using a tablet, prior to each consultation, with presentation of scores to clinicians) coupled with therapeutic information could have an impact on 12-month compliance with ET in patients with non-metastatic BC.

Methods: In this study, we will include 342 women with non-metastatic hormone receptor-positive BC with an indication for treatment with ET. Patients will be randomly assigned 1:1 by minimization and stratified by age, stage, type of ET prescribed, and presence of comorbidities (or not) in two arms. The intervention will consist of numerical HRQoL assessment using the CHES (Computer-based Health Evaluation System) software before each consultation (with delivery of scores to clinicians) coupled with therapeutic information. Therapeutic information will consist of three workshops related to understanding the prescription, nutrition, and fatigue. A reminder letter will be sent to patients every month. Patients in the control group will follow standard care. HRQoL will be assessed using a classic "paper-pencil" collection at baseline in both arms to ensure comparability between arms and at 12 months. The primary endpoint is 12-month compliance with ET. Patient satisfaction with care and the clinicians' perception of the usefulness of routine HRQoL assessment will also be assessed.

Discussion: This study will allow clinicians to identify and better understand the areas in which patients who receive ET have difficulties and thus it will assist clinicians with patient management. Systematic evaluation of HRQoL could provide an additional endpoint for measuring patients' health status and treatment-related symptoms, including ET. If the results of this study are positive, this intervention could be proposed as an integral part of daily clinical practice in patients who receive ET.

Trial registration: ClinicalTrials.govNCT04176809. Registered Nov. 25, 2019.

Keywords: Breast cancer; Compliance; Endocrine therapy; Health-related quality of life; Therapeutic information.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions, and assessments

References

    1. Huiart L, Bardou VJ, Giorgi R. L’adhésion thérapeutique aux traitements oraux: enjeux en oncologie - l’exemple du cancer du sein [The importance of adherence to oral therapies in the field of oncology: the example of breast cancer] Bull Cancer. 2013;100(10):1007–1015. doi: 10.1684/bdc.2013.1830.
    1. Ayres LR, Baldoni Ade O, Borges AP, Pereira LR. Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. Int J Clin Pharm. 2014;36:45–55. doi: 10.1007/s11096-013-9833-5.
    1. Hugtenburg JG, Timmers L, Elders PJ, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adherence. 2013;7:675–682. doi: 10.2147/PPA.S29549.
    1. Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, Axon RN, Zhao Y, et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35(12):2533–2539. doi: 10.2337/dc12-0572.
    1. Cheung WY, Lai EC, Ruan JY, Chang JT, Setoguchi S. Comparative adherence to oral hormonal agents in older women with breast cancer. Breast Cancer Res Treat. 2015;152(2):419–427. doi: 10.1007/s10549-015-3455-7.
    1. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–478. doi: 10.1007/s10549-012-2114-5.
    1. Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol. 2013;36(2):181–187. doi: 10.1097/COC.0b013e3182436ec1.
    1. Hsieh KP, Chen LC, Cheung KL, Chang CS, Yang YH. Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women--an Asian population-based study. PLoS One. 2014;9(2):e87027. doi: 10.1371/journal.pone.0087027.
    1. Taketani K, Tokunaga E, Yamashita N, Tanaka K, Akiyoshi S, Okada S, et al. Early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. Surg Today. 2014;44(10):1841–1846. doi: 10.1007/s00595-013-0762-7.
    1. Hadji P, Blettner M, Harbeck N, Jackisch C, Lück H-J, Windemuth-Kieselbach C, et al. The Patient’s Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013;24(6):1505–1512. doi: 10.1093/annonc/mds653.
    1. Ziller V, Kyvernitakis I, Knöll D, Storch A, Hars O, Hadji P. Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment--the COMPAS study. BMC Cancer. 2013;13:407. doi: 10.1186/1471-2407-13-407.
    1. Markopoulos C, Neven P, Tanner M, Marty M, Kreienberg R, Atkins L, et al. Does patient education work in breast cancer? Final results from the global CARIATIDE study. Future Oncol. 2015;11(2):205–217. doi: 10.2217/fon.14.179.
    1. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2010;73(2):156–166. doi: 10.1016/j.critrevonc.2009.02.001.
    1. Madan A, Borckardt JJ, Connell A, Book SB, Campbell S, Gwynette MF, et al. Routine assessment of patient-reported outcomes in behavioral health: room for improvement. Qual Manag Health Care. 2010;19(1):70–81. doi: 10.1097/QMH.0b013e3181ccbc53.
    1. Epplein M, Zheng Y, Zheng W, Chen Z, Gu K, Penson D, et al. Quality of life after breast cancer diagnosis and survival. J Clin Oncol. 2011;29(4):406–412. doi: 10.1200/JCO.2010.30.6951.
    1. Takada K, Kashiwagi S, Fukui Y, Goto W, Asano Y, Morisaki T, et al. Prognostic value of quality-of-life scores in patients with breast cancer undergoing preoperative chemotherapy. BJS Open. 2018;3(1):38–47. doi: 10.1002/bjs5.50108.
    1. Chu WO, Dialla PO, Roignot P, Bone-Lepinoy MC, Poillot ML, Coutant C, et al. Determinants of quality of life among long-term breast cancer survivors. Qual Life Res. 2016;25(8):1981–1990. doi: 10.1007/s11136-016-1248-z.
    1. Lavdaniti M, Owens DA, Liamopoulou P, Marmara K, Zioga E, Mantzanas MS, et al. Factors influencing quality of life in breast cancer patients six months after the completion of chemotherapy. Diseases. 2019;7(1):26. doi: 10.3390/diseases7010026.
    1. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714–724. doi: 10.1200/JCO.2004.06.078.
    1. Basch E, Dueck AC, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial [published correction appears in J Clin Oncol 2016;34(18):2198] [published correction appears in J Clin Oncol 2019;37(6):528] J Clin Oncol. 2016;34(6):557–565. doi: 10.1200/JCO.2015.63.0830.
    1. Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, et al. Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients [published correction appears in J Natl Cancer Inst 2018;110(4):436]. J Natl Cancer Inst. 2017;109(9). 10.1093/jnci/djx029.
    1. Pinheiro LC, Wheeler SB, Reeder-Hayes KE, Samuel CA, Olshan AF, Reeve BB. Investigating associations between health-related quality of life and endocrine therapy underuse in women with early-stage breast cancer. J Oncol Pract. 2017;13(5):e463–e473. doi: 10.1200/JOP.2016.018630.
    1. Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014;32(14):1480–1501. doi: 10.1200/JCO.2013.53.5948.
    1. Ruland CM, Andersen T, Jeneson A, Moore S, Grimsbø GH, Børøsund E, et al. Effects of an internet support system to assist cancer patients in reducing symptom distress: a randomized controlled trial. Cancer Nurs. 2013;36(1):6–17. doi: 10.1097/NCC.0b013e31824d90d4.
    1. Eggersmann TK, Harbeck N, Schinkoethe T, Riese C. eHealth solutions for therapy management in oncology. Breast Cancer Manag. 2018;6(3):101–106. doi: 10.2217/bmt-2017-0005.
    1. Holzner B, Giesinger JM, Pinggera J, Zugal S, Schöpf F, Oberguggenberger AS, et al. The Computer-based Health Evaluation Software (CHES): a software for electronic patient-reported outcome monitoring. BMC Med Inform Decis Mak. 2012;12:126. doi: 10.1186/1472-6947-12-126.
    1. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–144. doi: 10.1200/JCO.1998.16.1.139.
    1. Velikova G, Keding A, Harley C, Cocks K, Booth L, Smith AB, et al. Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. Eur J Cancer. 2010;46(13):2381–2388. doi: 10.1016/j.ejca.2010.04.030.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365.
    1. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group . EORTC QLQ-C30 scoring manual. 3. Brussels: EORTC; 2001.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74. doi: 10.1097/00005650-198601000-00007.
    1. Lepine JP, Godchau M, Brun P. Anxiety and depression in inpatients. Lancet. 1985;2(8469–70):1425–1426. doi: 10.1016/s0140-6736(85)92589-9.
    1. Costet N, Lapierre V, Benhamou E, Le Galès C. Reliability and validity of the Functional Assessment of Cancer Therapy General (FACT-G) in French cancer patients. Qual Life Res. 2005;14(5):1427–1432. doi: 10.1007/s11136-004-5531-z.
    1. Conroy T, Mercier M, Bonneterre J, Luporsi E, Lefebvre JL, Lapeyre M, et al. French version of FACT-G: validation and comparison with other cancer-specific instruments. Eur J Cancer 2004;40(15):2243–2252. doi:10.1016/j.ejca.2004.06.010.
    1. Brédart A, Anota A, Young T, Tomaszewski KA, Arraras JI, Moura De Albuquerque Melo H, et al. Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7). Eur J Cancer Care (Engl). 2018;27(1). 10.1111/ecc.12786.
    1. Rascle N, Bruchon-Schweitzer M, Sarason IG. Short form of Sarason’s Social Support Questionnaire: French adaptation and validation. Psychol Rep. 2005;97(1):195–202. doi: 10.2466/pr0.97.1.195-202.
    1. Bruchon-Schweitzer M. Psychologie de la santé. Modèles, concepts et méthodes. 1er éd. Paris: Dunod; 2002.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren